Spectranetics Corp (SPNC) versus Lumenis (LMNS) Head to Head Analysis

Lumenis (NASDAQ: LMNS) and Spectranetics Corp (NASDAQ:SPNC) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, risk, profitability, analyst recommendations and valuation.

Earnings & Valuation

This table compares Lumenis and Spectranetics Corp’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Lumenis N/A N/A N/A N/A N/A
Spectranetics Corp N/A N/A N/A ($1.59) -24.18

Profitability

This table compares Lumenis and Spectranetics Corp’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Lumenis 2.40% 6.50% 2.39%
Spectranetics Corp -32.93% -194.18% -23.25%

Analyst Recommendations

This is a summary of current recommendations and price targets for Lumenis and Spectranetics Corp, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lumenis 0 0 0 0 N/A
Spectranetics Corp 0 8 0 0 2.00

Spectranetics Corp has a consensus price target of $34.83, indicating a potential downside of 9.41%. Given Spectranetics Corp’s higher possible upside, analysts clearly believe Spectranetics Corp is more favorable than Lumenis.

Insider & Institutional Ownership

92.0% of Spectranetics Corp shares are owned by institutional investors. 3.7% of Spectranetics Corp shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

About Lumenis

Lumenis Ltd. (Lumenis) is a provider of energy-based, minimally invasive clinical solutions. The Company operates through three segments: surgical, ophthalmic and aesthetic. The Company offers energy-based solutions for medically necessary and elective procedures, primarily for the aging population. Its solutions include the holmium laser, the Lumenis Pulse 120H, used for urologic applications; the VersaPulse PowerSuite platform which uses holmium lasers for urologic applications; the M22 multi-energy, a multi-application platform for the treatment of various skin conditions, and the Selecta multi-modality platform for retinal, secondary cataract and glaucoma therapies. It offers products to hospitals, outpatient clinics, ambulatory surgery centers, physicians’ offices, private clinics and aesthetic chains. Its locations include Yokneam, Israel, where surgical and aesthetic products are manufactured, and Salt Lake City, Utah, where ophthalmic products are manufactured.

About Spectranetics Corp

The Spectranetics Corporation develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company’s products are used to cross, prepare and treat arterial blockages in the heart and legs and to manage pacemaker and defibrillator cardiac leads. Its geographic segments are U.S. Medical and International Medical. Its product offerings in U.S. Medical segment include medical devices used in minimally invasive procedures within the cardiovascular system, including fiber-optic devices and non-fiber-optic products (disposables), an excimer laser system (equipment) and the service of the excimer laser system (service). Its products are used in multiple vascular procedures, including peripheral atherectomy, crossing arterial blockages, coronary atherectomy and thrombectomy. Its International Medical segment is primarily engaged in distribution activities.

What are top analysts saying about Lumenis Ltd? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Lumenis Ltd and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit